Congenital erythrocytosis [PDF]
INTRODUCTION: Congenital erythrocytosis is by definition present from birth. Patients frequently present in childhood or as young adults and a family history may be present.
McMullin, M F
core +6 more sources
A Prospective Observational Study: Are There Any Relationships Between Erythrocytosis, Renal Tubular–Glomerular Functions, and Systemic Hypertension in Adolescent Male Idiopathic Erythrocytosis Patients? [PDF]
Background: Childhood hypertension is an important predictor of adult cardiovascular disease. Idiopathic erythrocytosis in adolescent males is characterized by elevated hemoglobin and hematocrit levels, which may increase blood viscosity and potentially ...
Nesrin Tas +3 more
doaj +2 more sources
Myomatous erythrocytosis syndrome: a critical diagnosis in women with uterine leiomyoma: a case report [PDF]
Background Myomatous erythrocytosis syndrome is an uncommon paraneoplastic syndrome of erythrocytosis associated with benign uterine leiomyomas. Fewer than 70 cases have been reported globally, and clinical awareness remains limited. Case presentation We
Soheila Aminimoghaddam +2 more
doaj +2 more sources
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study [PDF]
Background Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, widely used for type 2 diabetes and cardiorenal conditions, may induce erythrocytosis, potentially increasing cardiovascular risk.
Ji Yun Lee +16 more
doaj +2 more sources
Vaping‐Induced Erythrocytosis Resolved With Cessation of e‐Cigarette Use [PDF]
Vaping use is a global health concern with multiple adverse general health effects. We report a young man with vaping‐induced erythrocytosis that resolved following cessation of e‐cigarette use.
Jenyvette Hsia +4 more
doaj +2 more sources
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study [PDF]
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) increase haemoglobin and haematocrit levels, potentially causing secondary erythrocytosis—defined as a haemoglobin level above 16.5 g/dL in men and 16.0 g/dL in women—which is associated with ...
Abdullahi Ahmed Mohamed +15 more
doaj +2 more sources
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females [PDF]
: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly recognized as a common cause of drug-induced erythrocytosis. SGLT2 inhibitor–induced erythropoiesis may increase blood viscosity and precipitate thromboembolism, particularly in ...
Yohei Doi +3 more
doaj +2 more sources
Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes [PDF]
This study aimed to determine if sodium-glucose co-transporter-2 inhibitors (SGLT2i) use in diabetic patients leads to erythrocytosis and increases the incidence of arterial and venous thrombosis events. This is a retrospective cohort study using records
Yu-Han Chen +8 more
doaj +2 more sources
Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs [PDF]
Testosterone is the cornerstone therapy for men with hypogonadism, and also treats any associated anaemia by promoting erythropoiesis. However, excessive doses cause erythrocytosis (raised red cell mass), especially if other risk factors are present ...
Federica Tramontana +3 more
doaj +2 more sources
Congenital erythrocytosis [PDF]
AbstractErythrocytosis, or increased red cell mass, may be labeled as primary or secondary, depending on whether the molecular defect is intrinsic to the red blood cells/their precursors or extrinsic to them, the latter being typically associated with elevated erythropoietin (EPO) levels.
Nabhajit Mallik +3 more
openaire +2 more sources

